Bayer Diagnostics misses 2003 operating result target
This article was originally published in Clinica
Bayer Diagnostics failed to meet its target of a "slightly below 10%" operating result in 2003, the German group announced yesterday. The business unit's sales slipped by 5.2% to Euros1.9bn.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.